MIRA INFORM REPORT

Report Date :

26.09.2014

IDENTIFICATION DETAILS

Name :	TRIDENT CHEMPHAR LIMITED
Registered Office :	SY. No. 66 and 67, Miyapur, Hyderabad-500050, Andhra Pradesh
Country :	India
Financials (as on) :	31.03.2012
Date of Incorporation :	21.02.2007
Com. Reg. No.:	01-052901
Capital Investment / Paid-up Capital :	Rs.50.000 Millions
CIN No.: [Company Identification No.]	U24232AP2007PLC052901
TAN No.: [Tax Deduction & Collection Account No.]	HYDT02886C
PAN No.: [Permanent Account No.]	AAEFT8416H
Legal Form :	A Closely Held Public Limited Liability Company
Line of Business :	Trading in Chemicals Minerals and Mines.
No. of Employees :	Not Divulged

ECGC Country Risk Classification List – June 1, 2014

Country Name	Previous Rating (31.03.2014)	Current Rating (01.06.2014)
India	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

INDIAN ECONOMIC OVERVIEW

N E W S

Verdict Implications : Apex court order may alter coal import dynamics. Traders go slow on talks over coal supply contracts, uncertainty over cancellation of blocks weigh on stocks.

Recent arrest of the Chennai head of the Registrar of Companies, the ministry of corporate affairs arm that ensures that companies file all the information required by the Companies Act is the latest manifestation of a messy fight between a father and his adopted son for the control of Rs 40000 mn business empire. The Central Bureau of Investigation arrested Manumeethi Cholan after he accepted Rs 10 lakhs as bribe from M A M Ramaswamy, a CBI official said.

Central Bureau of Investigation books Electrotherm for cheating Central Bank of Rs 4360 mn.

Infosys maintains revenue guidance. COO Rao says attrition still an area of concern and it would take a few more quarters to bring down levels to 13-15 %.

DHL  to invest Euro 100 mn in India over next 2 years. The firm has chosen India to pilot its e-commerce business model for the Asia-Pacific region.

Blackstone may buy stake in BlueRidge SEZ in line with the fund’s real estate strategy in India.

Kingfisher Airlines Ltd grounded in October 2012 under the weight of heavy debt and accumulated losses, recently approached the Delhi high court for relief in two separate cases. The airline challenged a notice by Punjab & National Bank alleging that It had wilfully defaulted on Rs 7700 mn of loans and sought more time to comply with the requirements under the listing agreements with the Stock Exchanges.

OnMobile likely to sack another 300 employees. The lay-offs follow a spate of senior-level exits over the past two years, starting with of its founder. The overall lay-offs could number around 600 and are driven by the need to cut costs, says a former employee.

RBI DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2014.

LOCATIONS

Registered Office :	SY. No. 66 and 67, Miyapur, Hyderabad-500050, Andhra Pradesh, India
Tel. No.:	91-40-40408055/ 40408080
Fax No.:	91-40-40408060
E-Mail :	cs@aurobindo.com seshaiah.gelli@axisclinicals.com

DIRECTORS

As on 26.09.2013

Name :

Mr. Gelli Venkata Seshaiah

Designation :

Director

Address :

2-1-186/1, Flat No. 201, Sree Residency, Nallakunta, Hyderabad - 500044, Andhra Pradesh, India

Date of Birth/Age :

30.06.1949

Date of Appointment :

21.02.2007

Din No.:

00778048

Other Directorship:

S.No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24232AP2007PLC052901	TRIDENT CHEMPHAR LIMITED	Director	21/02/2007	21/02/2007	-	Active	NO
2	U24231AP2006PLC051148	VERITAZ HEALTHCARE LIMITED	Whole-time director	01/10/2012	06/11/2010	-	Active	NO
3	U24232AP2011PLC076052	STEPS THERAPEUTICS LIMITED	Director	18/08/2011	18/08/2011	-	Active	NO
4	U74999DL2011PLC224400	VAXER PHARMA LIMITED	Director	30/08/2011	30/08/2011	16/01/2014	Active	NO
5	U24232AP2010PTC069638	HYACINTHS PHARMA PRIVATE LIMITED	Director	20/09/2012	29/03/2012	01/11/2013	Active	NO
6	U45209AP2013PLC085417	MAHIRA INFRA AND REALTY LIMITED	Director	18/01/2013	18/01/2013	-	Strike off	NO

Name :

Subramani Suresh

Designation :

Whole Time Director

Address :

Flat No. G1, Gyaneswari Nilayam, H. No. 8-3-677/11, Yellareddy Guda, Hyderabad - 600060, Andhra Pradesh, India

Date of Birth/Age :

31.05.1957

Date of Appointment :

05.12.2013

Din No.:

02633641

Other Directorship:

S.No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24232AP2007PLC052901	TRIDENT CHEMPHAR LIMITED	Director	05/12/2013	21/02/2007	-	Active	NO
2	U24231AP2006PLC051148	VERITAZ HEALTHCARE LIMITED	Director	28/09/2011	06/11/2010	-	Active	NO

Name :

Mr. Sashi Kumaran Parambath

Designation :

Director

Address :

6-3-1219-12/202, Methadist Colony, Begumpet, Hyderabad-500016, Andhra Pradesh, India

Date of Birth/Age :

24.08.1967

Date of Appointment :

30.11.2009

Din No.:

02752493

Other Directorship:

S.No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24232AP2007PLC052901	TRIDENT CHEMPHAR LIMITED	Director	30/11/2009	01/08/2009	-	Active	NO
2	U24231AP2006PLC051148	VERITAZ HEALTHCARE LIMITED	Director	28/09/2011	06/11/2010	-	Active	NO

Name :

Mr. Rohit Reddy Penaka

Designation :

Director

Address :

Plot No. 46, Siddartha Nagar, Behind Vengal Rao Nagar, Hyderabad - , Andhra Pradesh, India

Date of Birth/Age :

01.10.1988

Date of Appointment :

27.09.2010

Din No.:

02624136

Other Directorship:

S.No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24232AP2007PLC052901	TRIDENT CHEMPHAR LIMITED	Director	27/09/2010	27/01/2010	-	Active	NO
2	U70102AP2010PTC070535	ROSA AVENUES INDIA PRIVATE LIMITED	Director	23/09/2010	23/09/2010	-	Strike off	NO
3	U74999DL2011PLC224400	VAXER PHARMA LIMITED	Director	30/08/2011	30/08/2011	16/01/2014	Active	NO
4	U24232AP2011PTC076791	SACHA CHEMPHAR PRIVATE LIMITED	Whole-time director	01/10/2012	30/09/2011	-	Active	NO
5	U26100AP2009PLC065810	COGENT GLASS LIMITED	Director	02/01/2012	02/01/2012	30/04/2013	Active	NO
6	U40300AP2012PTC084829	MAHIRA POWER SYSTEMS PRIVATE LIMITED	Director	14/12/2012	14/12/2012	-	Active	NO
7	U45209AP2013PLC085417	MAHIRA INFRA AND REALTY LIMITED	Director	18/01/2013	18/01/2013	-	Strike off	NO
8	U40101KA2001PTC029130	PAVANA GANGA POWER PRIVATE LIMITED	Director	01/06/2013	01/06/2013	-	Active	NO
9	U24232AP2014PLC092422	AURYN LABS LIMITED	Director	20/01/2014	20/01/2014	-	Active	NO

Name :

Penaka sarath chandra reddy

Designation :

Director

Address :

Plot No. 46/8-3-169, Siddartha Nagar, Behind Vengal Rao Nagar, Hyderabad - 500038, Andhra Pradesh, India

Date of Birth/Age :

22.02.1985

Date of Appointment :

21.02.2007

Din No.:

01628013

Other Directorship:

S.No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24239AP2004PLC044102	TRIDENT LIFE SCIENCES LIMITED	Director	18/09/2009	16/03/2006	-	Amalgamated	NO
2	U67120AP2006PTC050599	PVR HOLDINGS PRIVATE LIMITED	Director	11/07/2006	11/07/2006	-	Active	NO
3	U67120AP2007PLC052813	AXIS CLINICALS LIMITED	Whole-time director	10/09/2011	17/02/2007	-	Active	NO
4	U24232AP2007PLC052901	TRIDENT CHEMPHAR LIMITED	Director	21/02/2007	21/02/2007	-	Active	NO
5	L24239AP1986PLC015190	AUROBINDO PHARMA LTD	Director	27/09/2007	27/09/2007	-	Active	NO
6	U74999DL2009PTC191842	AURONEXT PHARMA PRIVATE LIMITED	Director	30/07/2010	20/08/2009	-	Active	NO
7	U24239AP2006PLC052053	APL HEALTHCARE LIMITED	Director	31/07/2010	25/11/2009	-	Active	NO
8	U24116AP2006PLC051171	APL RESEARCH CENTRE LIMITED	Director	31/07/2010	25/11/2009	-	Active	NO
9	U70102AP2010PTC070535	ROSA AVENUES INDIA PRIVATE LIMITED	Director	23/09/2010	23/09/2010	-	Strike off	NO
10	U24232AP2011PTC076791	SACHA CHEMPHAR PRIVATE LIMITED	Director	30/09/2011	30/09/2011	30/11/2012	Active	NO
11	U24232AP2012PLC078350	AURO PEPTIDES LIMITED	Director	02/01/2012	02/01/2012	-	Active	NO
12	U24232AP2012PLC081892	AUROBINDO ANTIBIOTICS LIMITED	Director	10/07/2012	10/07/2012	-	Active	NO
13	U73100AP2012PLC082225	AXIS CLINICALS INDIA LIMITED	Director	30/07/2012	30/07/2012	-	Active	NO
14	U24232AP2013PLC087101	CUREPRO PARENTERALS LIMITED	Director	12/09/2013	19/04/2013	-	Active	NO
15	U24232AP2013PLC091383	AUROZYMES LIMITED	Director	28/11/2013	28/11/2013	-	Active	NO
16	U24232AP2014PLC092422	AURYN LABS LIMITED	Director	20/01/2014	20/01/2014	-	Active	NO

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

As on 26.09.2013

Names of Shareholders	No. of Shares
Penaka Sarath Chandra Reddy	4999400
Subramani Suresh	100
Gelli Venkata Seshaiah	100
Gorla Madhu	100
Gopala Krishna Rao Kandula	100
K.V. Murali	100
B Samba Siva Reddy	100
Total	5000000

Equity Share Break up (Percentage of Total Equity)

As on 26.09.2013

Category	Percentage
Directors or relatives of Directors	99.99
Other	0.01
Total	100.00

BUSINESS DETAILS

Line of Business :

Trading in Chemicals Minerals and Mines.

Products :

Item Code No.	Product Description
29051100	Methanol
29321100	Tetra Hydro Furan
27072000	Toluene

GENERAL INFORMATION

No. of Employees :

Not Divulged

Bankers :

· Yes Bank Limited, 9th Floor, Nehru Centre, Discovery of India, Dr. Annie Besant Road, Worli, Mumbai - 400018, Maharashtra, India

· Andhra Bank, Somajiguda Branch, 6-3-352/2, Astral Heights, Road No. 1, Banjara Hills, Hyderabad - 500082, Andhra Pradesh, India

· Uti Bank Limited, 6-3-879/B, Greenlandroad, Begumpet, Hyderabad - 500016, Andhra Pradesh, India

Facilities :

Secured Loan	31.03.2012 (Rs. in Millions)	31.03.2011 (Rs. in Millions)
Long-term Borrowings
Rupee term loans from banks	1.354	0.000
Term loans from others	0.000	120.000
Short-term borrowings
Rupee term loans from banks	372.636	230.111
Rupee term loans from others	140.000	80.000
Total	513.990	430.111

Banking Relations :	--
Auditors :
Name :	K. Nagaraju and Associates Chartered Accountants
Address :	No. 1-8-197, Chikadpally, Hyderabad-500020, Andhra Pradesh, India
PAN N Income-tax PAN of auditor or auditor's firm :	AVHPK1930B
Enterprises which are owned, or have significant influence of or are partners with Key management personnel and their relatives:	· Aurobindo Pharma Limited, India [L24239AP1986PLC015190]
Subsidiary:	· Veritaz Healthcare Limited, India [U24231AP2006PLC051148]

CAPITAL STRUCTURE

As on 31.03.2012

Authorised Capital :

No. of Shares	Type	Value	Amount
15000000	Equity Shares	Rs.10/- each	Rs. 150.000 Millions

Issued, Subscribed & Paid-up Capital :

No. of Shares	Type	Value	Amount
5000000	Equity Shares	Rs.10/- each	Rs. 50.000 Millions

FINANCIAL DATA

[all figures are in Rupees Millions]

ABRIDGED BALANCE SHEET

SOURCES OF FUNDS	31.03.2012	31.03.2011
I.              EQUITY AND LIABILITIES
(1)Shareholders' Funds
(a) Share Capital	50.000	50.000
(b) Reserves & Surplus	(14.777)	(17.404)
(c) Money received against share warrants	0.000	0.000
(2) Share Application money pending allotment	0.000	0.000
Total Shareholders’ Funds (1) + (2)	35.223	32.596
(3) Non-Current Liabilities
(a) long-term borrowings	121.354	220.000
(b) Deferred tax liabilities (Net)	0.000	0.000
(c) Other long term liabilities	0.000	0.000
(d) long-term provisions	0.294	0.007
Total Non-current Liabilities (3)	121.648	220.007
(4) Current Liabilities
(a) Short term borrowings	512.636	310.111
(b) Trade payables	438.452	128.305
(c) Other current liabilities	162.357	207.792
(d) Short-term provisions	3.580	3.580
Total Current Liabilities (4)	1117.025	649.788
TOTAL	1273.896	902.391
II.          ASSETS
(1) Non-current assets
(a) Fixed Assets
(i) Tangible assets	2.751	0.000
(ii) Intangible Assets	0.000	0.000
(iii) Capital work-in-progress	0.000	0.000
(iv) Intangible assets under development	0.000	0.000
(b) Non-current Investments	526.610	504.110
(c) Deferred tax assets (net)	0.078	0.002
(d) Long-term Loan and Advances	15.600	6.000
(e) Other Non-current assets	0.000	0.000
Total Non-Current Assets	545.039	510.112
(2) Current assets
(a) Current investments	0.000	0.000
(b) Inventories	18.369	40.926
(c) Trade receivables	612.339	246.986
(d) Cash and cash equivalents	54.063	79.444
(e) Short-term loans and advances	40.864	23.616
(f) Other current assets	3.222	1.307
Total Current Assets	728.857	392.279
TOTAL	1273.896	902.391

SOURCES OF FUNDS		31.03.2010
SHAREHOLDERS FUNDS
1] Share Capital		50.000
2] Share Application Money		0.000
3] Reserves & Surplus		4.000
4] (Accumulated Losses)		(4.242)
NETWORTH		49.758
LOAN FUNDS
1] Secured Loans		123.345
2] Unsecured Loans		240.000
TOTAL BORROWING		363.345
DEFERRED TAX LIABILITIES		0.000
TOTAL		413.103
APPLICATION OF FUNDS
FIXED ASSETS [Net Block]		0.000
Capital work-in-progress		0.000
INVESTMENT		160.450
DEFERREX TAX ASSETS		5.005
CURRENT ASSETS, LOANS & ADVANCES
	Inventories	12.982
	Sundry Debtors	238.288
	Cash & Bank Balances	28.377
	Other Current Assets	13.104
	Loans & Advances	227.350
Total Current Assets		520.101
Less : CURRENT LIABILITIES & PROVISIONS
	Sundry Creditors	224.192
	Other Current Liabilities	48.383
	Provisions	0.056
Total Current Liabilities		272.631
Net Current Assets		247.470
MISCELLANEOUS EXPENSES		0.178
TOTAL		413.103

PROFIT & LOSS ACCOUNT

	PARTICULARS		31.03.2012	31.03.2011	31.03.2010
	SALES
		Income	1280.851	633.025	345.585
		Other Income	11.458	31.111	64.118
		TOTAL (A)	1292.309	664.136	409.703
Less	EXPENSES
		Purchases of stock-in-trade	1041.474	519.895
		Changes in inventories of finished goods, work-in-progress and stock-in-trade	22.557	(27.945)
		Employee benefit expense	5.450	3.807
		Other expenses	159.664	121.718
		Prior period items	(4.775)	1.669
		TOTAL (B)	1224.370	619.144	384.647
Less	PROFIT / (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C)		67.939	44.992	25.056
Less	FINANCIAL EXPENSES (D)		60.048	49.517	19.146
	PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E)		7.891	(4.525)	5.910
Less/ Add	DEPRECIATION/ AMORTISATION (F)		0.164	0.000	0.000
	PROFIT / (LOSS) BEFORE TAX (E-F) (G)		7.727	(4.525)	5.910
Less	TAX (H)		5.100	12.637	0.303
	PROFIT / (LOSS) AFTER TAX (G-H) (I)		2.627	(17.162)	5.607
	PROFIT / (LOSS)CARRIED TO BALANCE SHEET		NA	(21.404)	(4.242)
	IMPORTS
		Trading Goods	526.101	396.699	292.059
	TOTAL IMPORTS		526.101	396.699	292.059
	Earnings / (Loss) Per Share (Rs.)		0.53	0.00	1.12

KEY RATIOS

PARTICULARS		31.03.2012	31.03.2011	31.03.2010
PAT / Total Income	(%)	0.20	(2.58)	1.37
Net Profit Margin (PBT/Sales)	(%)	0.60	(0.72)	1.71
Return on Total Assets (PBT/Total Assets}	(%)	1.03	(1.14)	0.01
Return on Investment (ROI) (PBT/Networth)		0.22	(0.14)	0.12
Debt Equity Ratio (Total Debt /Networth)		18.00	16.26	7.30
Current Ratio (Current Asset/Current Liability)		0.65	0.60	1.91

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

DEBT EQUITY RATIO

Particular	31.03.2011	31.03.2012
	(Rs. In Millions)	(Rs. In Millions)
Share Capital	50.000	50.000
Reserves & Surplus	(17.404)	(14.777)
Net worth	32.596	35.223
long-term borrowings	220.000	121.354
Short term borrowings	310.111	512.636
Total borrowings	530.111	633.990
Debt/Equity ratio	16.263	17.999

YEAR-ON-YEAR GROWTH

Year on Year Growth	31.03.2010	31.03.2011	31.03.2012
	(Rs. In Millions)	(Rs. In Millions)	(Rs. In Millions)
Sales	345.585	633.025	1280.851
		83.175	102.338

NET PROFIT MARGIN

Net Profit Margin	31.03.2010	31.03.2011	31.03.2012
	(Rs. In Millions)	(Rs. In Millions)	(Rs. In Millions)
Sales	345.585	633.025	1280.851
Profit	5.607	(17.162)	2.627
	1.62%	(2.71%)	0.21%

LOCAL AGENCY FURTHER INFORMATION

Sr. No.	Check List by Info Agents	Available in Report (Yes / No)
1]	Year of Establishment	Yes
2]	Locality of the firm	Yes
3]	Constitutions of the firm	Yes
4]	Premises details	No
5]	Type of Business	Yes
6]	Line of Business	Yes
7]	Promoter's background	Yes
8]	No. of employees	No
9]	Name of person contacted	No
10]	Designation of contact person	No
11]	Turnover of firm for last three years	Yes
12]	Profitability for last three years	Yes
13]	Reasons for variation <> 20%	--
14]	Estimation for coming financial year	No
15]	Capital in the business	No
16]	Details of sister concerns	No
17]	Major suppliers	No
18]	Major customers	No
19]	Payments terms	No
20]	Export / Import details (if applicable)	No
21]	Market information	--
22]	Litigations that the firm / promoter involved in	--
23]	Banking Details	Yes
24]	Banking facility details	Yes
25]	Conduct of the banking account	--
26]	Buyer visit details	--
27]	Financials, if provided	Yes
28]	Incorporation details, if applicable	Yes
29]	Last accounts filed at ROC	No
30]	Major Shareholders, if available	Yes
31]	Date of Birth of Proprietor/Partner/Director, if available	Yes
32]	PAN of Proprietor/Partner/Director, if available	No
33]	Voter ID No of Proprietor/Partner/Director, if available	No
34]	External Agency Rating, if available	Yes

REVIEW OF OPERATIONS AND FUTURE PLANS

The company has achieved very good revenues, profit before depreciation interest and tax, during the financial year 2011-12, inspite of existing severe competition in the Industry. Revenue during the year has almost doubled compared to last year i.e., 95% increase over last year turnover. Similarly The Company has turned in to black and recording a profit of Rs.2.627 Millions as against losses during last year. The Company has shown a good performance inspite of high volatility in foreign currency resulting a foreign exchange fluctuation loss of Rs.49.000 Millions.

As a part of expansion strategy the company has recruited most experienced marketing and business development head. In line with other growth objectives, The Company has invested 22.500 Millions in M/s. Hyacinths Pharma Private Limited, which is a newly floated Indian company having business objective of manufacturing of Pharmaceutical related products.

During the year company has added new products like Toluene, IPA etc., to increase its revenue. Keeping in view the favorable market conditions and experienced talent added, the Company is projecting a turnover of Rs.2000.000 to 2250.000 Millions during the year 2012-13 with good margins. The company will maintain the same movementum in maintaining the all key parameters of growth and also to improve further in the ensuing years.

UNSECURED LOAN

PARTICULARS	31.03.2012 (Rs. in Millions)	31.03.2011 (Rs. in Millions)
Long-term Borrowings
Deposits from directors	30.000	0.000
Intercorporate deposits	90.000	100.000
Total	120.000	100.000

INDEX OF CHARGES

S.NO.	CHARGE ID	DATE OF CHARGE CREATION/MODIFICATION	CHARGE AMOUNT SECURED	CHARGE HOLDER	ADDRESS	SERVICE REQUEST NUMBER (SRN)
1	10405974	13/01/2014 *	700,000,000.00	YES BANK LIMITED	9TH FLOOR, NEHRU CENTRE, DISCOVERY OF INDIA, DR. ANNIE BESANT ROAD, WORLI, MUMBAI, MAHARASHTRA - 400018, INDIA	B96149265
2	10063582	28/12/2010 *	580,000,000.00	AXIS BANK LIMITED	CREDIT MANAGEMENT CENTRE, 5-2-183/184, III RD FLOOR, R P ROAD, SECUNDERABAD, HYDERABAD, ANDHRA PRADESH - 500003, INDIA	B05361845

FIXED ASSETS

Tangible assets

· Furniture and fixtures

· Vehicles

PRESS RELEASES

AUROBINDO TO ACQUIRE 60% STAKE IN AN UPCOMING MANUFACTURING FACILITY OF CELON LABORATORIES LIMITED

AUGUST 10, 2013

Hyderabad-based pharma player Aurobindo Pharma on Saturday informed the bourses that its board of directors had approved a couple of acquisitions and joint venture opportunities through a wholly owned subsidiary. However, the company did not disclose the name of the subsidiary.

According to the filing on the bourses, the company said that it will invest Rs 156.000 millions to acquire 60% stake in an upcoming manufacturing facility of Celon Laboratories Limited. The facility will manufacture hormonal and oncology products.

Apart from acquiring a majority stake in the firm, it will further invest Rs 323.000 millions over the next year towards completion and approval of the facility including new product developments in the hormonal and oncology area.

CMT REPORT (Corruption, Money Laundering & Terrorism]

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

1] INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

2] Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

3] Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

4] Record on Financial Crime :

Charges or conviction registered against subject: None

5] Records on Violation of Anti-Corruption Laws :

Charges or investigation registered against subject: None

6] Records on Int’l Anti-Money Laundering Laws/Standards :

Charges or investigation registered against subject: None

7] Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

8] Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

9] Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

10] Press Report :

No press reports / filings exists on the subject.

CORPORATE GOVERNANCE

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

CONTRAVENTION

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.61.02
UK Pound	1	Rs.99.43
Euro	1	Rs.77.84

INFORMATION DETAILS

Analysis Done by :	SUB
Report Prepared by :	MRI

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.